Injecting DNA into injured horse tendons and ligaments can cure lameness, new research involving scientists at Kazan Federal University, Moscow State Academy and The University of Nottingham has found.
The gene therapy technology was used in horses that had gone lame due to injury and within two to three weeks the horses were able to walk and trot. Within just two months they were back to full health, galloping and competing.
The study has big implications not just for the veterinary world but the future of human medicine – injuries like these are common in people as well as animals, not just in lameness but in other illnesses and diseases from the legs and arms through to the back and hips.
The new findings are the result of a partnership between the Kazan Federal University and Moscow State Academy of Veterinary Medicine and Biotechnology and Nottingham’s School of Veterinary Medicine and Science.
Dr Catrin Rutland, Assistant Professor of Anatomy and Developmental Genetics, led the work at Nottingham.
She said: “This pioneering study advances not only equine medicine but has real implications for how other species and humans are treated for lameness and other disorders in the future. The horses returned to full health after their injuries and did not have any adverse side effects. This is a very exciting medical innovation.”
The ground-breaking, international study, published in the academic journal Frontiers in Veterinary Science, demonstrated gene therapy using a combination of the Vascular Endothelial Growth Factor gene VEGF164, to enhance the growth of blood vessels and bone morphogenetic protein 2 (BMP2), which plays an important role in the development of bone and cartilage.
Both the genes were derived from horses, resulting in the biosynthesis of natural horse proteins in the treated animals. They were cloned into a single plasmid DNA, which is both biologically safe and unlikely to provoke an immune reaction from the body.
Current medical therapies have a relapse rate of 60 per cent and even the best regenerative medicine treatments have a 20 per cent relapse rate and take five to six months to work.
The new therapy is therefore very promising as it offers a much faster healing time and could significantly reduce relapse rates.
The results also showed that the tissue within the horses limbs has also fully recovered and 12 months after the revolutionary treatment the horses were completely fit, active and pain free.
Many medicines and treatments have adverse effects, but no side effects or bad reactions were seen in the horses treated.
Professor Albert Rizvanov, who led the study and is based at Kazan Federal University, said: “Advancing medicine, relieving pain and restoring function were the main aims of this study. We have shown that these are possible and within a much shorter time span than treatments available at the moment. In addition, we could use this type of therapy in other injuries and in many other situations ranging from fertility problems through to spinal cord injuries.
“Our next step is to secure more funding for an even larger trial to help more animals and improve and treat other disorders in the hope that one day we can routinely use this treatment around the world.”
The Latest on: Gene therapy
- UniQure gene therapy shows promising result in mid-stage trial on February 8, 2019 at 9:42 am
(Reuters) – Gene therapy company UniQure NV said on Friday its treatment for hemophilia B increased the levels of a protein that helps in blood clotting after 12 weeks in a relatively small study. Com... […]
- This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why on February 8, 2019 at 9:41 am
Gene therapy player Uniqure (QURE) could garner takeover interest, an analyst said Friday after the biotech unveiled promising data in hemophilia B treatment. Uniqure tested its gene therapy in three ... […]
- Gene therapy increases factor IX activity in severe hemophilia B on February 8, 2019 at 8:11 am
The investigational gene therapy AMT-061 showed increases in factor IX activity sustained at 25% to 51% of normal among patients with severe or moderately severe hemophilia B, according to updated cli... […]
- UniQure’s hemophilia B gene therapy clears another clinical test on February 8, 2019 at 6:02 am
UniQure has posted 12-week data on its hemophilia B gene therapy. The update suggests FIX activity increases seen at six weeks are sustainable, giving uniQure a boost as it races Spark Therapeutics to ... […]
- Publisher Correction: Improved TMC1 gene therapy restores hearing and balance in mice with genetic inner ear disorders on February 8, 2019 at 5:33 am
The original version of this Article contained errors in Fig. 5. In panels i and j the three rightmost x-axis labels inadvertently read ‘Tmc1’ instead of ‘Tmc2’. These errors have been corrected in bo... […]
- UniQure's gene therapy for hemophilia B continues to show treatment effect in mid-stage study; shares up 2% premarket on February 8, 2019 at 4:36 am
UniQure (NASDAQ:QURE) is up 2% premarket on light volume following its announcement of updated results from its open-label single-arm Phase 2b clinical trial evaluating gene therapy AMT-061 in ... […]
- UniQure gene therapy shows rise in blood-clotting protein in trial on February 8, 2019 at 4:35 am
(Reuters) - UniQure NV said on Friday its gene therapy to treat patients with a blood disorder, hemophilia B, increased the levels of a protein that helps in blood clotting after 12 weeks. The updated ... […]
- New DNA-based nanomachines can be used for gene therapy of cancer on February 7, 2019 at 11:50 pm
Scientists from ITMO in collaboration with their international colleagues proposed new DNA-based nanomachines that can be used for gene therapy of cancer. This new invention can greatly contribute to ... […]
- Tests Suggest Scientists Achieved 1st Gene Editing in the Body on February 7, 2019 at 4:41 pm
Preliminary results suggest that two men with a rare disorder now have a corrective gene at very low levels, which may not be enough to make the therapy a success. Still, it's a scientific milestone t... […]
- Solid Biosciences to soldier on as initial muscular dystrophy gene therapy results disappoint on February 7, 2019 at 3:47 am
Ilan Ganot, the co-founder and chief executive of biotech firm Solid Biosciences, left a career in investment banking to start the company in 2013 in order to search for treatments, and perhaps cures, ... […]
via Google News and Bing News